Facility

Teva Irvine California Injectable Manufacturing

Teva's Irvine, California sterile injectable manufacturing facility. This site was shut down by Teva in spring 2022 due to contamination and sterilization failures identified in FDA inspections — an event that caused a streptozocin shortage (rare pancreatic cancer drug) and contributed to broader oncology injectable market instability in 2022-2023 concurrent with the Intas/Accord cisplatin shutdown. The Irvine closure reduced available US generic injectable manufacturing capacity precisely when additional capacity was needed to offset the Intas disruption. The simultaneous Intas shutdown (cisplatin/carboplatin) and Teva Irvine shutdown (streptozocin) represented multiple independent quality-failure events at Indian and US generic injectable sites within the same 12-month window. Source: https://www.cidrap.umn.edu/resilient-drug-supply/life-threatening-cancer-drug-shortages-are-result-cascade-troubles